search

Active clinical trials for "Pancreatic Neoplasms"

Results 431-440 of 2501

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Accelerated Phase Chronic Myelogenous LeukemiaBCR-ABL1 Positive55 more

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.

Active66 enrollment criteria

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With...

B Cell LymphomaB Cell Leukemia4 more

A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets. CAR T cells are genetically engineered to express single-chain variable fragment (scFv) targeting indication-specific antigens. The investigational CAR T cells and proposed indications are as follows: CAR-CD19 T cells for B cell leukaemia/lymphoma; CAR-BCMA T cells for myeloma; CAR-GPC3 T cell for hepatocellular carcinoma; CAR-CLD18 T cells for pancreatic carcinoma and adenocarcinoma of esophagogastric junction.

Active104 enrollment criteria

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer....

Pancreatic Cancer Stage IIIPancreatic Cancer Stage IV

The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.

Active18 enrollment criteria

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or...

Extrahepatic Bile Duct AdenocarcinomaBiliary Type28 more

This phase Ib trial studies the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread to other places in the body. Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as durvalumab, may block tumor growth in different ways by targeting certain cells. Giving guadecitabine and durvalumab may work better in treating patients with liver, pancreatic, bile duct, or gallbladder cancer.

Active66 enrollment criteria

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Pancreatic Cancer

This research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: FOLFIRINOX which is made up of 4 different drugs: 5-Fluorouracil (5-FU) Oxaliplatin Irinotecan Leucovorin Losartan Nivolumab Radiation Therapy Surgery

Active49 enrollment criteria

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

KRAS NP_004976.2:p.G12DMetastatic Pancreatic Adenocarcinoma2 more

This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.

Active18 enrollment criteria

Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer

Pancreatic Cancer

The safety and efficacy of re-irradiation with stereotactic body radiotherapy for relapsed pancreatic cancer will be evaluated.

Active22 enrollment criteria

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF...

Locally Advanced Pancreatic CarcinomaMetastatic Pancreatic Carcinoma3 more

This phase II trial studies the side effects and how well the combination of binimetinib and encorafenib work in treating patients with pancreatic cancer with a somatic BRAF V600E mutation. Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and encorafenib may work better compared to the usual treatment in treating patients with pancreatic cancer and a somatic BRAF V600E mutation.

Active57 enrollment criteria

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced...

Pancreatic Cancer Non-resectable

This phase-2 monocenter non-randomized prospective clinical trial evaluates the effectiveness of minimally invasive microwave ablation plus immunotherapy for unresectable non-metastatic locally advanced pancreatic cancer.

Active20 enrollment criteria

A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine

Pancreatic Cancer

The purpose of this study is to evaluate the safety and feasibility of long term boost vaccination of a lethally irradiated, allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene alone or given in combination with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide for the treatment of patients with surgically resected adenocarcinoma of the head, neck, tail or the uncinate process of the pancreas.

Active20 enrollment criteria
1...434445...251

Need Help? Contact our team!


We'll reach out to this number within 24 hrs